Iloprost (Iloprost Trometamol)

Iloprost acts as a selective agonist of the IP (prostacyclin) receptor on vascular smooth‑muscle cells. Activation raises cyclic AMP levels, causing vasodilation of pulmonary and systemic vessels and inhibiting platelet aggregation, which together improve blood flow and reduce vascular resistance.

The dosing regimen for Iloprost is individualized. A qualified prescriber determines the infusion rate, concentration, and duration based on the patient’s clinical condition, response, and tolerance. No fixed dose can be stated without a medical prescription.

Safety data for Iloprost in pregnancy and lactation are limited. It is generally classified as contraindicated or to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Iloprost, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Iloprost is a short‑acting prostacyclin analog administered intravenously, whereas agents like epoprostenol are also IV but have a shorter half‑life, and treprostinil can be given subcutaneously or inhaled. Iloprost offers flexible dosing and a favorable safety profile, but selection depends on patient preference, disease severity, and logistical considerations.

Iloprost must be stored refrigerated at 2‑8 °C. Keep the solution in its original container, protect it from light, and avoid freezing or shaking. If a temporary temperature excursion occurs, discard the product according to local regulations.

Iloprost is given as an intravenous infusion, typically through a peripheral or central venous catheter. The infusion rate is set by the prescribing clinician and may be adjusted based on hemodynamic response and tolerability. Continuous monitoring of blood pressure and heart rate is recommended during administration.

The most serious adverse events include severe hypotension, pulmonary edema, significant bleeding due to its antiplatelet effect, thrombocytopenia, and life‑threatening arrhythmias. Patients should be monitored closely for these events, especially during the initial dosing period.

Iloprost is contraindicated in patients with known hypersensitivity to the drug or any prostacyclin analog, in those with uncontrolled severe hypotension, and in individuals with active bleeding disorders unless the benefits outweigh the risks. Caution is also advised for patients with severe hepatic or renal impairment.